山东大学耳鼻喉眼学报 ›› 2016, Vol. 30 ›› Issue (1): 80-82.doi: 10.6040/j.issn.1673-3770.0.2015.302

• 论著 • 上一篇    下一篇

玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析

邢凯1,亢泽峰2   

  1. 1.青海大学研究生院, 青海 西宁 810016;
    2.中国中医科学院眼科医院门诊眼科, 北京 100040
  • 收稿日期:2015-07-19 出版日期:2016-02-16 发布日期:2016-02-16
  • 通讯作者: 亢泽峰. E-mail:zefeng2531@163.com E-mail:cxingbkail@163.co
  • 作者简介:邢凯. E-mail:cxingbkail@163.co

Clinical analysis on intravitreal injection of conbercept in the treatment of macular edema secondary to branch retinal vein occlusion.

XING Kai1, KANG Zefeng   

  1. 1. Graduate School of Qinghai University, Xining 810016, Qinghai, China;2. Ophthalmology Clinic, Eye Hospital, China Academy of Chinese Medical Sciences, Beijing 100040, China
  • Received:2015-07-19 Online:2016-02-16 Published:2016-02-16

PDF (PC)

1123

被引次数

21

摘要： 目的 探讨玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)的临床疗效及安全性。 方法 选取BRVO继发ME患者33例(38眼)为研究对象,均经玻璃体腔内注射康柏西普眼用注射液0.05 mL。随访6个月期间,至少每个月检查1次,根据光学相干断层扫描(OCT)测量黄斑中心凹厚度以判断是否行再次注射。比较治疗前及治疗后1、3个月最佳矫正视力(BCVA),治疗前及治疗后1个月OCT结果,并观察治疗后1个月内并发症的发生情况。 结果 最小分辨率视力(VA)对数为(0.59±0.21),首次注射后1个月显著改善至(0.35±0.12)(P<0.01)。治疗前及治疗后1、3个月BCVA比较差异有统计学意义(P<0.05),且治疗后3个月BCVA明显高于治疗前(P<0.05)。治疗前及治疗后1个月视网膜黄斑中心凹厚度比较差异有统计学意义(P<0.05)。治疗后1个月内仅5例(15.15%)发生眼压一过性增高,未见其他明显眼不良事件。 结论 基于OCT的玻璃体腔内注射康柏西普治疗BRVO继发ME短期疗效确切,且具有较好的安全性。

关键词: 玻璃体, 黄斑水肿, 视网膜分支静脉阻塞, 康柏西普, 光学相干断层扫描

Abstract: Objective To explore the clinical efficacy and safety of intravitreal injection of conbercept in the treatment of macular edema(ME)secondary to branch retinal vein occlusion(BRVO). Methods A total of 33 patients(38 eyes)with ME secondary to BRVO were selected as research objects, and injected Conbercept Ophthalmic Injection 0.05 mL through vitreous cavity. The optic examination was conducted at least once a month during 6-mongh follow-up. The central foveal thickness was measured to judge whether the injection was given again using optical coherence tomography(OCT). The best corrected visual acuity(BCVA)before and 1, 3 months after treatment as well as OCT results before and 1 month after treatment were compared, and the complications within 1 month after treatment were observed. Results The logarithm of minimum visual resolution(VA)was(0.59±0.21), and improved to(0.35±0.12)after the first injection(P<0.01). There was statistical significance regarding the BCVA before and 1, 3 months after treatment(P<0.05), and the BCVA 3 months after treatment was dramatically higher than that before treatment(P<0.05). The difference was statistically significant regarding the central foveal thickness of retina before and 1 month after treatment(P<0.05). Within 1 month after treatment, only 5 patients(15.15%)suffered from transient increase of intraocular pressure, no other eye-related events occurred. Conclusion For ME secondary to BRVO, intravitreal injection of conbercept based on OCT has definite short-term efficacy and better safety.

Key words: Conbercept, Macular edema, Branch retinal vein occlusion, Optical coherence tomography

中图分类号: 

  • R774
[1] 艾伦(美), 姚静. 美国威尔斯眼科医院临床眼科图谱和精要: 视网膜病[M]. 上海:上海科学技术出版社, 2005: 101.
[2] 张承芬. 眼底病学[M]. 2版.北京:人民卫生出版社, 2010: 560-575.
[3] 张菁, 蔡小军, 陈晓敏, 等. 玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J]. 中华眼底病杂志, 2015, 31(1):22-26. ZHANG Jing, CAI Xiaojun, CHEN Xiaomin, et al. A prospective randomized clinical trial on intravitreal injection of Conbercept combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion[J]. Chin J Ocular Fundus Dis, 2015, 31(1):22-26.
[4] Donati S, Barosi P, Bianchi M, et al. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion[J]. Eur J Ophthalmol, 2012, 22(4):607-614.
[5] Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J]. PLoS ONE, 2013, 8(8):e70544.
[6] Wu Z, Zhou P, Li X, et al. Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling[J]. PLoS ONE, 2013, 8(3):e57642.
[7] 曲毅, 魏奉才. Wills眼科手册[M].5版. 济南:山东科学技术出版社, 2009: 434.
[8] 毕燃, 贾彩华, 于越, 等. 康柏西普治疗视网膜静脉阻塞黄斑水肿的临床观察[J].赤峰学院学报(自然科学版), 2014, 23:71-73. BI Ran, JIA Caihua, YU Yue, et al. Clinical observation of conbercept in the treatment of patients with macular edema secondary to branch retinal vein occlusion[J]. J Chifeng Univ(Nat Sci Ed), 2014, 23:71-73.
[9] Chen C H, Chen Y H, Wu P C, et al. Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection[J]. Chang Gung Med J, 2010, 33(4):424-435.
[10] Feng J, Zhao T, Zhang Y, et al. Differences in aqueous concentrations of cytokines In macular edema secondary to branch and central retinal vein occlusion[J]. PLoS ONE, 2013, 8(7):e68149.
[11] Pielen A, Mirshahi A, Fehgen N, et al. Ranibizumab for branch retinal vein occlusion associated macular edema study(RABAMES): six-month results of a prospective randomized clinical trial[J]. Acta Ophthalmol, 2015, 93(1):e29-37.
[12] Tsagkataki M, Papathomas T, Lythgoe D, et al. Twenty-four-month results of intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion[J]. Semin Ophthalmol, 2015, Aug 21:1-8, [Epub ahead of print].
[13] Hikichi T, Higuchi M, Matsushita T, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion[J]. Br J Ophthalmol, 2014, 98(2):195-199.
[14] 舒智宇. 康柏西普治疗视网膜静脉阻塞黄斑水肿的临床分析[J]. 延边医学, 2015, 12:47-48. SHU Zhiyu. Clinical analysis of conbercept for treating macular edema secondary to branch retinal vein occlusion[J]. Yanbian Med J, 2015, 12:47-48.
[1] 赵娟,焦万珍,赵博军. UWFSS-OCTA检测糖尿病视网膜病变微循环的变化[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 80-86.
[2] 朱明琼,李征,刘茹,田涛,彭婧利,吕倩怡,谭华霞. 基于OCT/OCTA的AI筛查系统在抗VEGF治疗糖尿病性黄斑水肿患者效果评价中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 68-73.
[3] 孙庆祝,沈健,陈星,吴雁冰,曾论. 代谢指标在预测糖尿病性黄斑水肿患者雷珠单抗疗效中的作用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 74-81.
[4] 朱云龙,王平,高萌. 误诊为中浆及视网膜炎的后巩膜炎1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 99-105.
[5] 李世强,马燕,王家伟. 光学相干断层扫描血管成像在全身疾病中的临床应用研究进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 127-134.
[6] 宋艳玲,司元元,崔彦. 微量玻璃体切除治疗激光笔致儿童全层黄斑裂孔1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 144-147.
[7] 丁术梁,王超凡,刘建亮. 眼内液检测指导精准治疗急性视网膜坏死1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 114-117.
[8] 王焕霞,王淑雅,王影,孙璇,黄杰,王兴荣. 孔源性视网膜脱离玻璃体切除术后继发黄斑前膜的危险因素分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 181-185.
[9] 李致富,高玉. 玻璃体切除术后视野缺损的机制研究及预防[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 168-176.
[10] 张露,王永晶,贾君,赵健楠,赵芳. 初发单眼眼前黑影飘动患者的光相干断层扫描特征[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 85-88.
[11] 肖哲,张胜娟,赵子琦,兴辰,李成泉,刘志强. Ultra Q:YAG激光治疗黄斑部视网膜前出血17例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 130-135.
[12] 黄娇,彭昌福. 甲状腺相关性眼病活动性客观评价的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 171-178.
[13] 辛梦,纪芳,代春华,张靖,刘澍. 医用透明质酸钠与平衡盐溶液在微创玻璃体手术中对眼表保护的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 58-65.
[14] 沈嘉琪,李潇飒,毕燕龙,张敬法. 人工智能在DME筛查、诊断和预后中的应用[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 153-159.
[15] 鲍莹,刘志高,姜鹏飞,崔文轩,郑晓霞,杨梦瑶,司明威,王玉,王红. 康柏西普治疗糖尿病合并CRVO-ME高反射点的临床观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 55-60.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发